Side-by-side · Research reference
SemaglutidevsVesugen
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AFDA-ApprovedFlagship15/53 cited
BAnimal-MechanisticHUMAN-REVIEWED5/43 cited
Semaglutide
GLP-1 RA · FDA-Approved
SQ · Abdomen / thigh / arm · Once weekly
Vesugen
Bioregulatory Tripeptide · Vascular Endothelium
3 AATripeptide
Endothelin-1 ↓Atherosclerotic tissue
Ki-67 ↑Aged endothelium
SQ / IM · Protocol varies
01Mechanism of Action
Parameter
Semaglutide
Vesugen
Primary target
GLP-1 receptor (GLP-1R)WEGOVY (semaglutide) injection 2021
Vascular endothelial cell nucleus — MKI67 gene promoter
Pathway
GLP-1R agonism → ↑glucose-dependent insulin secretion, ↓glucagon, ↓gastric emptying, ↓appetite via hypothalamic centresWilding 2021
KED → MKI67 promoter interaction (CATC binding motif -14 to +12 bp) → Ki-67 proliferation protein ↑
Downstream effect
Improved glycemic control, reduced caloric intake, body-weight reduction, cardiovascular risk reductionWilding 2021
Normalised endothelin-1 expression in atherosclerotic/restenotic endothelium, restored connexin expression for cell-cell communication, enhanced proliferative capacity in senescent endothelial culturesKozlov 2016Khavinson 2014
Feedback intact?
Glucose-dependent insulin release preserves physiological feedback
Not applicable — does not operate via hormone axis
Origin
Modified GLP-1(7-37) with two amino-acid substitutions and C-18 fatty-acid acylation for albumin binding and 168-h half-lifeWEGOVY (semaglutide) injection 2021
Khavinson bioregulatory peptide school — designed as tissue-specific (vascular) cytomodulator
Antibody development
—
—
02Dosage Protocols
Parameter
Semaglutide
Vesugen
Standard dose (weight, Wegovy)
2.4 mg / week (after 16-wk titration)WEGOVY (semaglutide) injection 2021Wilding 2021
—
Frequency
Once weekly, same day each week
Not specified in available literature
Titration schedule
0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg over 16 weeks
Mitigates GI side effects.
—
Evidence basis
FDA-approved · Phase 3 RCTsWilding 2021WEGOVY (semaglutide) injection 2021
Animal models (atherosclerosis, restenosis, aging) · Russian case series
Duration
Indefinite for chronic indication
Discontinuation results in weight regain.
Case series report treatment courses in elderly arterial insufficiency
Reconstitution
Pre-mixed pen device (commercial). Research lyophilised vial: bacteriostatic water per label.
—
Timing
Any time of day, with or without food
—
Half-life
~7 days (168 h)WEGOVY (semaglutide) injection 2021
Not reported
Tripeptides typically cleared rapidly.
Standard dose (reported)
—
Not standardised — Russian clinical case series
Protocols vary; no FDA-approved regimen.
Route
—
Subcutaneous or intramuscular
04Side Effects & Safety
Parameter
Semaglutide
Vesugen
Injection site reaction
Mild erythema, pruritus
—
Thyroid C-cell tumours
Boxed warning — contraindicated in MEN2 / personal or family MTC historyWEGOVY (semaglutide) injection 2021
—
Hypoglycemia
Low risk as monotherapy; elevated when combined with sulfonylureas / insulin
—
Gallbladder events
Increased cholelithiasis
—
Heart rate
Modest ↑ resting HR (~2-4 bpm)
—
Reported adverse events
—
None documented in available abstracts
Injection site
—
Assumed minimal — typical for small peptides
Long-term safety
—
Unknown — no long-term RCT data
Epigenetic mechanism risk
—
Theoretical concern: direct gene promoter interaction — proliferative effects in non-target tissues not characterised
Absolute Contraindications
Semaglutide
- ·Personal or family history of medullary thyroid carcinoma
- ·Multiple endocrine neoplasia syndrome type 2
- ·Pregnancy / breastfeeding
- ·Hypersensitivity to semaglutide
Vesugen
—Relative Contraindications
Semaglutide
- ·Severe gastroparesis
- ·History of pancreatitis
- ·Diabetic retinopathy (may worsen with rapid glycemic improvement)
Vesugen
- ·Active malignancy — proliferative mechanism (Ki-67 upregulation) untested in oncologic context
05Administration Protocol
Parameter
Semaglutide
Vesugen
1. Reconstitution / device
Commercial: pre-filled pen, no reconstitution. Research vial: per-label or bacteriostatic water.
Lyophilised powder reconstituted with sterile water or bacteriostatic water per supplier protocol. No standardised formulation.
2. Injection site
SQ — abdomen, thigh, or upper arm. Rotate sites weekly to avoid lipohypertrophy.
Subcutaneous (abdomen, thigh) or intramuscular. Rotate sites if multi-dose protocol.
3. Timing
Once weekly, same day. Day can be changed if ≥2 days separate doses.
No reported circadian or fasting requirement. Russian protocols typically integrated into geroprotective regimens.
4. Storage
Pen: refrigerate 2–8 °C unopened; room temp ≤30 °C up to 56 days after first use.
Lyophilised: refrigerate 2–8 °C, light-protected. Reconstituted: use immediately or refrigerate per supplier guidance (typically <7 days).
5. Needle
Pen-supplied 31–34G needle. Research vial: 27–31G insulin syringe.
—
06Stack Synergy
Semaglutide
+ Tirzepatide
WeakCombining two GLP-1 RA-class drugs is not clinically validated and risks additive GI toxicity. Tirzepatide's GIP component already provides complementary mechanism vs pure GLP-1; stacking with semaglutide adds receptor saturation but no synergy. NOT recommended.
- Note
- Stack not recommended — choose one GLP-1 RA
- Primary benefit
- (none — additive toxicity, no synergy)
Vesugen
+ Thymalin
Multi-pathwayBoth from Khavinson bioregulatory school. Thymalin targets thymic/immune axis, Vesugen targets vascular endothelium. Rationale: multi-system geroprotection in elderly — immune senescence + vascular aging. Documented in Khavinson-tradition protocols combining tissue-specific peptides for poly-organ rejuvenation. No direct synergy study; combinatorial logic based on distinct target tissues.
- Vesugen
- Per protocol (SQ/IM)
- Thymalin
- Per protocol (SQ/IM)
- Frequency
- Sequential or concurrent per geroprotective protocol
- Primary benefit
- Multi-system age-related decline mitigation (vascular + immune)